Filing Analysis
VolitionRx Limited issued a total of 773,361 shares of common stock to Lind Global Asset Management XII LLC to satisfy conversion obligations under existing senior secured convertible promissory notes. These issuances occurred on August 11 and August 20, 2026, totaling $400,000 in converted debt.
🚩 Red Flags
- Continued debt conversion: The company is actively converting senior secured debt into equity, which can lead to significant shareholder dilution.
- Reliance on existing creditors: The issuance is to a single institutional creditor (Lind Global Asset Management), indicating a reliance on debt financing to sustain operations.
📋 Key Facts
- Issued 220,264 shares on August 11, 2026, to satisfy a $150,000 conversion obligation.
- Issued 553,097 shares on August 20, 2026, to satisfy a $250,000 conversion obligation.
- The recipient is Lind Global Asset Management XII LLC, an existing securityholder.
- The shares were issued under the terms of a Securities Purchase Agreement (SPA) dated May 15, 2025 (amended Jan 7, 2026).
- The underlying debt consists of senior secured convertible promissory notes with original principal amounts of $7,500,000 and $2,400,000.
VolitionRx Limited announced its financial results and business updates for the quarter ended June 30, 2026. The filing serves as a formal notice of the earnings release and an upcoming conference call.
📋 Key Facts
- Financial results for the quarter ended June 30, 2026, were announced on August 13, 2026.
- A conference call to discuss results is scheduled for August 14, 2026, at 8:30 a.m. ET.
- The company furnished Exhibit 99.1 containing the press release.
VolitionRx Limited issued 290,697 shares of common stock to Lind Global Asset Management XII LLC on August 6, 2026, to satisfy a $200,000 conversion obligation under existing senior secured convertible promissory notes.
🚩 Red Flags
- Continued conversion of debt into equity suggests ongoing liquidity pressure or inability to meet cash obligations.
- Frequent issuance of shares to a single institutional holder (Lind Global Asset Management) can lead to significant dilution for existing shareholders.
📋 Key Facts
- Issued 290,697 shares of common stock to Lind Global Asset Management XII LLC on August 6, 2026.
- The issuance was made to satisfy a $200,000 conversion obligation under the SPA dated May 15, 2025 (amended Jan 7, 2026).
- Previous issuances to Lind include 116,651 shares on July 14, 2026 ($133,333 obligation) and 372,023 shares on July 16, 2026 ($416,666 obligation).
- The underlying debt consists of senior secured convertible promissory notes with original principal amounts of $7,500,000 and $2,400,000.
VolitionRx Limited held its 2026 annual meeting of stockholders where shareholders approved a significant reduction in authorized shares and elected seven directors. The filing also confirms the ratification of Sadler, Gibb & Associates, LLC as independent auditors.
🚩 Red Flags
- Significant reduction in authorized shares (from 325M to 150M) often precedes or accompanies a reverse stock split to improve share price/compliance.
- Low shareholder turnout at the annual meeting (approx. 49% of outstanding shares present).
📋 Key Facts
- Stockholders approved an amendment to reduce authorized common stock from 325,000,000 to 150,000,000 shares.
- The Annual Meeting was held on July 17, 2026, with approximately 49.3% of outstanding shares (4,261,161 of 8,627,191) represented in person or by proxy.
- Seven directors were elected to serve until the next annual meeting.
- Sadler, Gibb & Associates, LLC was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
- The 2026 Stock Incentive Plan was approved by stockholders.
VolitionRx issued common stock to Lind Global Asset Management XII LLC to satisfy payment obligations under a senior secured convertible promissory note. The issuance occurred in two tranches on May 19, 2026, and June 17, 2026.
🚩 Red Flags
- Use of convertible debt to fund operations often leads to significant shareholder dilution in micro-cap companies.
- The company is paying down debt with equity rather than cash, which may indicate liquidity constraints.
📋 Key Facts
- Issued 333,332 shares on June 17, 2026, to satisfy a $416,666 payment obligation.
- Issued 212,259 shares on May 19, 2026, to satisfy a $416,666 payment obligation.
- Shares were issued as part of a senior secured convertible promissory note with an original principal amount of $7,500,000.
- The counterparty is Lind Global Asset Management XII LLC.
- The issuance relied on exemptions Section 3(a)(9) or 4(a)(2) of the Securities Act and/or Rule 506 of Regulation D.
VolitionRx Limited completed a public offering of 2,960,000 shares of common stock and 1,480,000 accompanying warrants at a combined price of $1.55 per share and warrant. The offering closed on June 9, 2026, raising approximately $4.1 million in net proceeds.
🚩 Red Flags
- Use of proceeds includes the repayment of existing secured convertible notes, which may indicate pressure from debt holders.
- Dilution from the issuance of nearly 3 million shares and 1.48 million warrants.
📋 Key Facts
- Net proceeds from the offering are approximately $4.1 million.
- Potential additional gross proceeds from full exercise of warrants: $2.3 million.
- Offering price: $1.55 per Share and accompanying Warrant.
- Warrants have a 5-year term and an exercise price of $1.55.
- Proceeds are earmarked for research, product development, clinical studies, commercialization, working capital, and repayment of secured convertible notes.
- Maxim Group LLC served as the placement agent with a $75,000 reimbursement for out-of-pocket expenses.
VolitionRx Limited (VNRX) entered into a waiver and consent agreement with Lind Global Asset Management XII LLC on May 21, 2026, after the company breached a Market Capitalization Covenant on its two outstanding senior secured convertible promissory notes totaling $9.9M in original principal. While Lind waived acceleration and foreclosure rights stemming from the covenant breach, the violation triggered a 10% penalty on outstanding principal balances and grants Lind enhanced conversion rights at a discount to market price. This filing signals significant financial stress and potential dilution risk for existing shareholders.
🚩 Red Flags
- Market capitalization covenant breach signals the company's market cap has fallen to distressed levels relative to its debt obligations
- 10% penalty on outstanding principal of BOTH notes adds a material incremental liability (estimated ~$990,000 based on original principals of $9.9M combined)
- Enhanced conversion price mechanism — at 90% of average of 3 lowest VWAPs over 20 trading days — creates significant dilution pressure at discounted prices
- Notes are SENIOR SECURED, meaning Lind holds collateral claims over company assets in any default scenario
- Waiver is narrowly scoped: only covers Market Capitalization Covenant; all other default triggers remain active
- Lind retains preserved rights under the Notes as explicitly carved out in the Waiver, indicating ongoing covenant risk
- Inability to maintain minimum market cap suggests deteriorating equity value and potential ongoing financial distress
- Discounted conversion rights effectively create a 'death spiral' financing dynamic if stock continues to decline
📋 Key Facts
- Company breached the Market Capitalization Covenant under two senior secured convertible promissory notes held by Lind Global Asset Management XII LLC
- Note 1 (2025 Note): $7,500,000 original principal, issued May 15, 2025
- Note 2: $2,400,000 original principal, issued January 7, 2026 under amended and restated securities purchase agreement
- Total original principal across both Notes: $9,900,000
- Waiver and Consent executed May 21, 2026, filed May 22, 2026
- Covenant breach triggered a 10% penalty on the Outstanding Principal Amount of EACH Note
- Lind waived rights to declare amounts due, demand immediate payment, accelerate obligations, or foreclose on collateral arising from this specific covenant breach
- Lind retains right to convert outstanding principal into common stock at the LOWER of: (i) then-current Conversion Price, or (ii) 90% of the average of the three lowest VWAPs over the 20 prior trading days
- Conversion is subject to a 4.99% beneficial ownership cap
- Notes are senior secured, meaning Lind holds a security interest in company assets
- Waiver document will be filed as exhibit to 10-Q due no later than August 14, 2026
- Common stock trades on NYSE American under ticker VNRX
Mickie Henshall notified the Board of VolitionRx Limited on May 12, 2026, that she will not stand for re-election at the 2026 Annual Meeting of Stockholders. Following her departure, the Board will reduce its size from eight to seven directors.
📋 Key Facts
- Director Mickie Henshall notified the Board of her decision not to stand for re-election on May 12, 2026.
- Ms. Henshall has served as a director since August 2022.
- The Company stated there were no disagreements regarding operations, policies, or practices.
- The Board of Directors will be reduced from eight to seven members effective immediately prior to the 2026 Annual Meeting.
VolitionRx Limited announced its financial results for the first quarter ended March 31, 2026, and scheduled a conference call to discuss business updates.
📋 Key Facts
- Released Q1 2026 financial results for the period ended March 31, 2026
- Scheduled a conference call for May 15, 2026, at 8:30 a.m. U.S. Eastern Time
- The report was furnished under Item 2.02 (Results of Operations and Financial Condition)
- The filing includes a press release as Exhibit 99.1
VolitionRx Limited has implemented a 1-for-20 reverse stock split of its common stock, effective April 28, 2026. The action follows stockholder approval granted on March 31, 2026, and involves an amendment to the company's Certificate of Incorporation.
🚩 Red Flags
- Reverse stock split (1-for-20 ratio) is a significant consolidation often used to maintain exchange listing requirements.
- The high ratio (1:20) suggests the share price had likely fallen significantly below the $1.00 minimum bid price threshold common for NYSE American or Nasdaq listings.
📋 Key Facts
- The reverse stock split ratio is set at 1-for-20.
- The split became effective at 12:01 a.m. ET on April 28, 2026.
- A Certificate of Third Amendment was filed with the Delaware Secretary of State on April 27, 2026.
- The Board of Directors determined the specific ratio within a range previously authorized by stockholders.
- The split affects the treatment of fractional shares, though specific cash-out or rounding terms were not detailed in the summary text.
VolitionRx Limited received notification from NYSE American that its plan to regain compliance with listing standards has been accepted. The company is currently in violation of stockholders' equity requirements due to persistent net losses and has until August 6, 2027, to meet the minimum equity thresholds.
🚩 Red Flags
- Reported net losses in five most recent fiscal years.
- Stockholders' equity has fallen below the $2.0 million, $4.0 million, and $6.0 million tiered requirements.
- Potential for delisting proceedings if periodic milestones in the compliance plan are not met.
📋 Key Facts
- NYSE American accepted the company's compliance plan on April 22, 2026.
- The company has been granted a 'Plan Period' until August 6, 2027, to regain compliance.
- The company is in violation of Sections 1003(a)(i), (ii), and (iii) of the NYSE American Company Guide.
- The company failed to maintain minimum stockholders' equity of $6.0 million despite reporting net losses in its five most recent fiscal years.
- The company is not currently eligible for the $50 million market capitalization exemption.
VolitionRx Limited has announced a 1-for-20 reverse stock split of its common stock, effective April 28, 2026. The split is being implemented to satisfy terms within financing agreements with Lind Global Asset Management XII LLC.
🚩 Red Flags
- Significant 1-for-20 reverse stock split, often a sign of share price weakness.
- The split is explicitly linked to financing terms with Lind Global Asset Management, suggesting restrictive covenants or pressure from institutional lenders.
📋 Key Facts
- The reverse stock split ratio is set at 1-for-20.
- The split is expected to become effective at 12:01 a.m. ET on April 28, 2026.
- The action follows shareholder approval granted at a special meeting on March 31, 2026.
- The split is necessitated by financing documents with Lind Global Asset Management XII LLC dated May 20, 2025, and January 15, 2026.
- No fractional shares will be issued; instead, fractional entitlements will be rounded up to the next whole share.
VolitionRx stockholders approved a reverse stock split and a significant share issuance to Lind Global Asset Management. The reverse split ratio is authorized between 1-for-5 and 1-for-20, while the share issuance exceeds 20% of the company's outstanding common stock.
🚩 Red Flags
- Approval of a reverse stock split, typically a defensive measure to maintain exchange listing requirements.
- Significant dilutive event involving the issuance of more than 20% of the company's equity to a single institutional investor (Lind Global Asset Management).
📋 Key Facts
- Special meeting of stockholders held on March 31, 2026.
- Stockholders approved a reverse stock split with a ratio ranging from 1-for-5 to 1-for-20.
- Approval granted for the issuance of common stock exceeding 20% of outstanding shares to Lind Global Asset Management XII LLC.
- As of the February 9, 2026 record date, there were 135,565,326 shares of common stock outstanding.
- The share issuance was required to comply with NYSE American Rule 713.
VolitionRx Limited announced its financial results for the fourth quarter and full fiscal year ended December 31, 2025. The company scheduled a conference call for April 1, 2026, to discuss these results and provide business updates.
📋 Key Facts
- Financial results released for the fiscal year ended December 31, 2025
- Conference call scheduled for April 1, 2026, at 8:30 a.m. U.S. Eastern Time
- The filing was made under Item 2.02 (Results of Operations and Financial Condition)
- Press release dated March 31, 2026, was included as Exhibit 99.1
VolitionRx Limited is repaying a $7.5M senior secured convertible note held by Lind Global Asset Management by issuing massive quantities of common stock at deeply discounted prices (~$0.21-$0.23/share). In roughly one month, the company issued 6,419,867 shares to satisfy just $1,416,666 in repayment obligations, representing a classic toxic convertible ("death spiral") financing structure that severely dilutes existing shareholders.
🚩 Red Flags
- Toxic convertible note structure — Lind Global is a well-known provider of death spiral financing to micro-cap companies, where conversion prices decline with the stock, creating relentless dilution
- Massive dilution: 6.4M+ shares issued in one month to satisfy only ~$1.4M of a $7.5M obligation; at this rate, tens of millions more shares may be required to fully retire the note
- Extremely low implied conversion prices ($0.213-$0.227/share) suggest the stock is trading near penny-stock levels, raising NYSE American continued listing compliance risk
- The SPA was amended and restated on January 7, 2026, just 8 months after the original agreement — may indicate deteriorating terms or company difficulties
- Senior secured status of the note means Lind has priority claim over all company assets in a default scenario
- Additional overhang from 483,870 warrants at $0.682 exercise price from the September 2025 private placement
- Repeated unregistered issuances to a single institutional lender indicates dependence on dilutive financing
📋 Key Facts
- $7,500,000 senior secured convertible promissory note issued to Lind Global Asset Management XII LLC under SPA dated May 15, 2025 (amended/restated January 7, 2026)
- Feb 17, 2026: 1,956,178 shares issued to satisfy $416,666 payment (~$0.213/share implied price)
- Jan 29, 2026: 2,569,753 shares issued to satisfy $583,334 payment (~$0.227/share implied price)
- Jan 16, 2026: 1,893,936 shares issued to satisfy $416,666 payment (~$0.220/share implied price)
- Total: 6,419,867 shares issued in ~1 month to repay only $1,416,666 of the $7.5M note
- Separate private placement on Sep 18, 2025: 483,870 shares + 483,870 warrants (exercise price $0.682) for $300,000 ($0.62/share combined price)
- Warrants from September placement expire September 18, 2030
- Note is senior secured, giving Lind priority claim on company assets
- All issuances made under Section 3(a)(9), 4(a)(2), and/or Rule 506 of Reg D exemptions
VolitionRx Limited received a notice from NYSE American stating it is in non-compliance with stockholder equity requirements due to sustained net losses. The company must submit a compliance plan by March 8, 2026, to avoid delisting proceedings.
🚩 Red Flags
- Delisting notice from NYSE American
- Failure to meet minimum stockholder equity standards due to persistent net losses
- Ineligibility for market cap exemptions suggests low valuation/market cap relative to requirements
- Risk of delisting if the compliance plan is rejected or not met by August 2027
📋 Key Facts
- Received notice of non-compliance from NYSE American on February 6, 2026.
- Non-compliance relates to Section 1003(a)(i), (ii), and (iii) regarding minimum stockholder equity requirements ($2M, $4M, and $6M thresholds).
- The company is ineligible for exemptions, including the market capitalization exemption (> $50 million).
- Must submit a compliance plan to NYSE American by March 8, 2026.
- Deadline to regain compliance under the proposed plan is August 6, 2027.
- Shares will trade with a '.BC' (below compliance) designation on the NYSE American.
VolitionRx Limited entered into an amended securities purchase agreement with Lind Global Asset Management XII LLC to receive $2,000,000 in funding via a Senior Secured Convertible Promissory Note and a Common Stock Purchase Warrant. This follows a previous $7.5 million issuance to the same lender in May 2025.
🚩 Red Flags
- High dilution risk due to convertible note and warrants (7M+ warrant shares plus conversion/repayment shares).
- Debt is secured by a first-priority security interest in all company assets.
- Restrictive negative covenants: limits borrowing, asset sales, distributions, and stock repurchases.
- Event of Default triggers include market cap falling below a threshold or failure to file SEC reports.
- Repayment mechanism allows for significant equity dilution via the 'Repayment Share Price' discount.
📋 Key Facts
- Company will receive $2,000,000 in funding from Lind Global Asset Management XII LLC.
- Issuance of a Senior Secured Convertible Promissory Note (the 'Lind Note') in the principal amount of $2,400,000.
- Issuance of a Common Stock Purchase Warrant for 7,000,350 shares at $0.5714 per share.
- The Lind Note is non-interest bearing and repayable in 18 consecutive monthly installments of $133,333 starting six months from issuance.
- Repayment can be made in cash (at a 1.05x premium) or common stock at a 'Repayment Share Price' (90% of the 20-day VWAP).
- The Lind Note is secured by a first-priority security interest in all of the Company's assets.
- Includes an ownership limitation clause: issuance subject to stockholder approval if aggregate shares exceed 19.99% of outstanding common stock.
VolitionRx's majority-owned subsidiary, Volition Veterinary Diagnostics Development, LLC, has terminated its CEO, Dr. Salvatore Thomas Butera, effective January 31, 2026. The termination is part of a cost-realignment effort that includes the elimination of the CEO position within the subsidiary.
🚩 Red Flags
- Elimination of a C-suite position (CEO) suggests significant restructuring or cost-cutting measures.
- The move is explicitly framed as 'cost-realignment efforts', which can indicate liquidity or operational pressure in micro-cap companies.
📋 Key Facts
- Dr. Salvatore Thomas Butera will depart as CEO of Volition Veterinary on January 31, 2026.
- The decision is attributed to 'operational reasons' and not due to any disagreement regarding company operations or policies.
- The Chief Executive Officer position at Volition Veterinary will be eliminated following the departure.
- Dr. Butera is expected to transition to a part-time consulting role after January 31, 2026.
VolitionRx Limited filed an amended 8-K to correct a typographical error and report the exercise of an over-allotment option by Newbridge Securities Corporation. The Underwriter exercised its option to purchase 1,194,000 shares and 1,732,500 warrants at a combined price of $0.52 per unit.
🚩 Red Flags
- Significant dilution: The offering involves millions of new shares and warrants, which heavily dilutes existing shareholders.
- Low stock price: Offering price is $0.52, indicating the company is operating in a low-price/penny stock territory.
- Warrant overhang: Large number of warrants (over 13 million total including original offering) creates significant future dilution pressure.
📋 Key Facts
- Underwriter (Newbridge Securities Corp) exercised over-allotment option for 1,194,000 Common Stock shares and 1,732,500 warrants.
- Combined offering price to the public: $0.52 per share/warrant unit ($0.51 for share, $0.01 for warrant).
- Net proceeds from the over-allotment exercise: approximately $582,426 after expenses and discounts.
- The Underwriter was issued additional warrants to purchase 83,580 shares at an exercise price of $0.63 per share.
- Amendment allows the underwriter to exercise options for shares or warrants separately rather than as a combined unit.
VolitionRx Limited announced its financial results and business updates for the fiscal quarter ended September 30, 2025. The company scheduled a conference call to discuss these results on November 14, 2025.
📋 Key Facts
- Financial results and business updates were released for the quarter ended September 30, 2025.
- A conference call is scheduled for November 14, 2025, at 8:30 a.m. ET.
- The announcement was made via press release (Exhibit 99.1).
VolitionRx Limited filed an amended 8-K to correct typographical errors in a previously reported underwriting agreement and to announce the exercise of an over-allotment option by Newbridge Securities Corporation. The amendment allows for more flexible exercise of options regarding shares and warrants.
🚩 Red Flags
- Significant dilution: The offering of over 11.5 million shares plus warrants represents substantial potential dilution for existing shareholders.
- Low share price: Offering price of $0.52 per share is characteristic of highly speculative micro-cap/penny stock financing.
📋 Key Facts
- The company is conducting an underwritten public offering of 11,550,000 common shares at $0.52 per share plus a warrant.
- Underwriter Newbridge Securities Corporation exercised its over-allotment option on November 7, 2025.
- The exercise included the purchase of 1,194,000 Option Shares and 1,732,500 Option Warrants.
- Warrants are exercisable for up to 83,580 shares at a combined price/structure related to the offering.
VolitionRx Limited announced that its underwriter, Newbridge Securities Corporation, has exercised a portion of its over-allotment option. This involves the purchase of 1,194,000 additional shares and 1,732,500 warrants at a combined price of $0.52 per unit.
🚩 Red Flags
- Significant dilution: The offering involves millions of new shares and warrants at a very low price point ($0.52).
- Warrant overhang: The issuance of 1,732,500 additional warrants creates potential future dilution for existing shareholders.
📋 Key Facts
- Underwriter exercised Over-Allotment Option on November 7, 2025.
- Exercise includes 1,194,000 additional Common Stock shares and 1,732,500 warrants.
- Combined offering price is $0.52 per unit ($0.51 for share, $0.01 for warrant).
- The Underwriter exercised the option to purchase a mix of shares and warrants rather than both together, following an amendment to the original agreement.
VolitionRx Limited announced a significant public offering of 11.55 million shares at $0.52 per share, accompanied by warrants, to raise approximately $5.4 million in net proceeds. The company disclosed critically low cash reserves of approximately $0.3 million as of September 30, 2025.
🚩 Red Flags
- Extremely low cash position ($0.3M) relative to typical micro-cap operating needs.
- Significant dilution via the issuance of 11.55 million new shares and 11.55 million warrants.
- Warrant overhang: The exercise price ($0.60) is higher than the offering price ($0.52), but the sheer volume of warrants creates significant future dilution.
- The company's cash position as of Sept 30, 2025, suggests a near-term liquidity crisis was imminent prior to this offering.
📋 Key Facts
- Public offering of 11,550,000 shares of common stock at $0.52 per share.
- Accompanying warrants to purchase up to 11,550,000 shares at an exercise price of $0.60.
- Net proceeds estimated at approximately $5.4 million after expenses.
- Company reported approximately $0.3 million in cash and cash equivalents as of September 30, 2025.
- Underwriter (Newbridge Securities Corporation) to receive warrants for up to 929,775 shares at $0.63 exercise price.
- Certain directors and officers participated in the offering by purchasing 254,229 shares.
VolitionRx Limited announced its financial results and business updates for the quarter ended June 30, 2025. The company scheduled a conference call to discuss these results on August 15, 2025.
📋 Key Facts
- Reported quarterly results for the period ending June 30, 2025.
- Scheduled a conference call for August 15, 2025, at 8:30 a.m. ET to discuss business updates and financial condition.
- The filing is an announcement of earnings (Item 2.02) rather than a disclosure of specific material changes or transactions.
VolitionRx Limited announced a registered direct offering of common stock and warrants to insiders and existing stockholders. The offering aims to raise approximately $1.21 million in gross proceeds to fund research, clinical studies, and working capital.
🚩 Red Flags
- Related-party transaction: The offering is being conducted specifically to directors and executive officers (Insiders) and existing stockholders.
- Dilution risk: Issuance of a significant number of shares and warrants (1.7M+ units) will result in substantial dilution for common shareholders.
- Low capital raise: $1.21 million is a relatively small amount, suggesting ongoing liquidity needs or 'bridge' financing behavior.
📋 Key Facts
- Offering date: August 1, 2025
- Total gross proceeds (excluding warrant exercise): $1.21 million
- Issuance of 156,250 shares to Insiders at $0.64 per share.
- Issuance of 1,734,375 shares and warrants to Warrant Investors at $0.64 per unit.
- Warrants have an exercise price of $0.768 per share.
- Warrants are exercisable from August 5, 2025, through August 5, 2030.
VolitionRx Limited held its annual meeting of stockholders on June 18, 2025. The meeting resulted in the election of eight directors and the approval of an amendment to increase authorized shares.
🚩 Red Flags
- Significant increase in authorized shares (from 175M to 325M) provides management with significant capacity for future dilution through equity offerings.
📋 Key Facts
- Stockholders approved a Certificate of Second Amendment increasing authorized common stock from 175,000,000 to 325,000,000 shares.
- Eight members were elected to the Board of Directors to hold office until the 2026 annual meeting.
- Stockholders ratified Sadler, Gibb & Associates, LLC as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
- A non-binding advisory vote approved executive compensation packages.
- The Amendment to the Certificate of Incorporation became effective upon filing with the Secretary of State of Delaware on June 18, 2025.
VolitionRx Limited announced its financial results and business updates for the quarter ended March 31, 2025. The company scheduled a conference call to discuss these results on May 16, 2025.
📋 Key Facts
- Financial results and business updates for the quarter ended March 31, 2025 were released on May 15, 2025.
- A conference call is scheduled for May 16, 2025, at 8:30 a.m. ET to discuss the results.
VolitionRx Limited entered into a new $7.5 million 'at the market' (ATM) sales agreement with JonesTrading Institutional Services LLC and simultaneously terminated its previous $25 million ATM agreement with Jefferies LLC.
🚩 Red Flags
- Significant reduction in total ATM capacity from $25 million (Jefferies) to $7.5 million (JonesTrading), suggesting a more conservative or constrained liquidity strategy.
- Continuous need for equity financing to fund operations/clinical studies is characteristic of high-burn micro-cap biotech companies.
📋 Key Facts
- Entered into a Capital On Demand Sales Agreement with JonesTrading Institutional Services LLC on April 22, 2025.
- The new agreement allows for the sale of up to $7.5 million in common stock via ATM offerings.
- Terminated a prior Equity Distribution Agreement with Jefferies LLC (dated May 20, 2022) effective April 20, 2025.
- The previous program had an aggregate offering price of up to $25 million.
- Sales Agent commission is set at up to 3.0% of gross proceeds.
- Proceeds are intended for research, product development, clinical studies, and working capital.
VolitionRx Limited filed a Form S-1 registration statement to register 35,867,306 shares of common stock issuable upon the exercise of previously issued warrants. This is a re-registration of existing warrant shares rather than an issuance of new equity for immediate capital raising.
🚩 Red Flags
- Potential for significant dilution if warrant holders choose to exercise and sell the resulting shares.
📋 Key Facts
- Filed Form S-1 on April 4, 2025.
- Registering 35,867,306 shares of common stock (Warrant Shares).
- Shares are issuable upon the exercise of previously issued warrants.
- The registration aims to replace/withdraw these shares from a previous S-3 Shelf Registration Statement filed on September 24, 2021.
VolitionRx Limited issued an 8-K to furnish its quarterly and fiscal year financial results for the period ended December 31, 2024. The filing serves as a formal announcement of earnings and business updates via a press release.
📋 Key Facts
- Reported date: March 31, 2025
- Covers financial results for the quarter and fiscal year ended December 31, 2024
- Includes an announcement of a conference call held on March 31, 2025, at 4:30 p.m. ET
- Financial results were furnished via Exhibit 99.1
VolitionRx Limited entered into a securities purchase agreement on March 24, 2025, to conduct a registered direct offering of common stock and warrants. The offering aims to raise approximately $2.3 million in gross proceeds from insiders and new investors.
🚩 Red Flags
- Significant dilution: Issuance of over 4.1 million new shares (including potential warrant exercises) represents substantial dilution to existing shareholders.
- Warrant overhang: The issuance of warrants with an exercise price ($0.66) slightly above the offering price ($0.55) creates significant future dilution pressure.
- Insider involvement: A large portion of the offering is directed toward directors, executive officers, and existing stockholders (Insiders).
📋 Key Facts
- Total gross proceeds: Approximately $2.3 million (before expenses).
- Issuance of 2,363,636 common shares to Insiders at $0.55 per share.
- Issuance of 1,739,087 common shares and warrants to Warrant Investors at $0.55 per unit.
- Warrants allow purchase of up to 1,739,087 shares at an exercise price of $0.66 per share.
- Warrants are exercisable from March 26, 2025, until March 26, 2030.
- Proceeds intended for R&D, clinical studies, product commercialization, and working capital.
VolitionRx Limited entered into a securities purchase agreement on December 5, 2024, to conduct a registered direct offering of common stock and warrants. The offering aims to raise approximately $1.9 million in gross proceeds to fund research, clinical studies, and working capital.
🚩 Red Flags
- Significant dilution risk due to issuance of over 3 million new shares and associated warrants.
- Warrant overhang: The issuance of Form A and Form B warrants creates potential future dilution at various price points.
- Small offering size ($1.9M) relative to typical micro-cap needs, suggesting continuous need for capital.
📋 Key Facts
- Offering size: Approximately $1.9 million in gross proceeds.
- Securities offered: 445,648 shares of common stock to Insiders at $0.5722/share; 2,857,389 shares of common stock to Warrant Investors at $0.5722/share plus warrants.
- Warrant terms: Form A Warrants (exercise price $0.5722) and Form B Warrants (exercise price $0.71525), exercisable from Dec 9, 2024, to Dec 9, 2029.
- Insider participation: Certain directors and executive officers are participating in the sale of common stock but did not receive warrants.
VolitionRx Limited issued an 8-K to furnish its quarterly financial results and business updates for the period ending September 30, 2024. The filing serves as a formal announcement of the upcoming earnings release and scheduled conference call.
📋 Key Facts
- Financial results for the quarter ended September 30, 2024 were released on November 14, 2024.
- A conference call to discuss the results is scheduled for November 15, 2024, at 8:30 a.m. ET.
- The filing includes Exhibit 99.1 containing the full press release of the financial and business updates.
VolitionRx Limited announced the appointment of Timothy Still to its Board of Directors and as non-executive Chairman, effective November 6, 2024. The move expands the Board size to eight members.
🚩 Red Flags
- Significant equity-based compensation (RSUs) tied to high stock price targets ($2.50 and $5.00), which may indicate a desire to incentivize rapid share price appreciation.
📋 Key Facts
- Timothy Still appointed as Director and non-executive Chairman effective Nov 6, 2024.
- Board size increased from seven to eight members.
- Compensation includes $30,000 per quarter for services.
- Grant of 400,000 RSUs vesting in three equal installments over 36 months.
- Performance-based RSU grant of 1,000,000 shares contingent on stock price targets ($2.50 and $5.00) being met for 30 consecutive trading days.
- Additional annual RSU awards of up to 300,000 shares subject to corporate goals.
VolitionRx Limited announced the appointment of Dr. Ethel Rubin to its Board of Directors, effective September 30, 2024. The appointment increases the board size to seven members and includes seats on the Audit and Compensation Committees.
🚩 Red Flags
- None identified in this filing.
📋 Key Facts
- Dr. Ethel Rubin appointed as Director, effective September 30, 2024.
- Board size increased from six to seven members.
- Dr. Rubin appointed to both the Audit Committee and the Compensation Committee.
- Compensation includes $10,840 per calendar quarter and a grant of 15,000 RSUs vesting over three years (12, 24, and 36 months).
- Dr. Rubin is deemed an independent director by the Board.
VolitionRx Limited announced new employment and consulting agreements for Dr. Gaetan Michel, effective September 1, 2024. These agreements involve complex multi-entity arrangements where the executive serves as CEO/COO across various subsidiaries (Belgian Volition, Volition Global Services, and Volition America) via a third-party management company.
🚩 Red Flags
- Complex related-party structure involving a management company (3F Management SRL) for executive services.
- Executive holds multiple high-level roles across various international subsidiaries, complicating oversight and governance.
- Compensation is paid through multiple channels (direct employment + third-party consulting fees), which can obscure total cost to the parent company.
📋 Key Facts
- Dr. Gaetan Michel entered into an employment agreement with Belgian Volition SRL effective Sept 1, 2024.
- Michel to receive €12,000/month salary plus benefits (car/fuel ~€1,500/month) and potential bonuses of up to €28,500.
- Volition Global Services SRL entered into an amendment with 3F Management SRL effective Sept 1, 2024.
- 3F Management will provide Dr. Michel's services for a monthly fee of €12,797 (increasing to €15,598 on Nov 1, 2024).
- Dr. Michel holds multiple roles: CEO of Belgian Volition and Volition America, COO of the Company/subsidiaries, and Manager/President of Volition Veterinary Diagnostics Development LLC.
- The company claims combined aggregate compensation is materially consistent with prior levels.
VolitionRx Limited has released a brief overview of certain oncology assets within its portfolio for potential out-licensing purposes via its licensing adviser, PharmaVentures Limited. This is a Regulation FD disclosure intended to provide information to third parties regarding the company's intellectual property.
📋 Key Facts
- The filing was made on September 16, 2024, under Item 7.01 (Regulation FD Disclosure).
- The company is providing an overview of oncology assets available for out-licensing.
- PharmaVentures Limited is acting as the Company's licensing adviser.
- Information provided in Exhibit 99.1 is furnished but not 'filed' under Section 18 of the Exchange Act.
VolitionRx Limited announced its financial results and business updates for the quarter ended June 30, 2024. The filing serves as a formal notice of the earnings release and an upcoming conference call.
📋 Key Facts
- Reporting period: Quarter ended June 30, 2024.
- Earnings announcement date: August 14, 2024.
- Scheduled conference call: August 15, 2024, at 8:30 a.m. U.S. Eastern Time.
VolitionRx Limited entered into a securities purchase agreement for a $7.0 million registered direct offering of common stock and various warrants to an institutional investor. The proceeds are intended for research, clinical studies, and working capital.
🚩 Red Flags
- Significant dilution: The offering includes millions of shares and warrants, including pre-funded warrants that are almost equivalent to equity.
- Complex warrant structures: Series A and B warrants have specific milestones (FDA approval/commercial deals) that could lead to further dilution upon achievement of clinical or commercial goals.
- High cost of capital: The 8.0% cash fee plus legal and non-accountable expenses increases the net proceeds burden.
📋 Key Facts
- Total gross proceeds from the offering: $7.0 million.
- Issuance of 9,170,000 shares of common stock at $0.55 per share.
- Issuance of 3,557,273 pre-funded warrants at $0.549 per warrant (exercise price $0.001).
- Issuance of Series A and Series B warrants with an exercise price of $0.57 per share.
- Placement agent H.C. Wainwright & Co., LLC to receive an 8.0% cash fee plus other expenses.
- Series B Warrants include a milestone trigger related to FDA approval or significant commercial agreements.
VolitionRx Limited held its annual meeting of stockholders on July 2, 2024. Stockholders approved several key items including a new stock incentive plan and an amendment to the certificate of incorporation to increase authorized shares.
🚩 Red Flags
- Significant increase in authorized share count (from 100M to 175M) suggests potential future dilution via equity financing or stock-based compensation.
📋 Key Facts
- Stockholders approved the 2024 Stock Incentive Plan, authorizing up to 7,500,000 shares of common stock for issuance under awards.
- Stockholders approved a Certificate of Amendment increasing authorized shares from 100,000,000 to 175,000,000 shares.
- Six members were elected to the Board of Directors: Dr. Phillip Barnes, Dr. Alan Colman, Mickie Henshall, Guy Innes, Kim Nguyen, and Cameron Reynolds.
- Stockholders ratified Sadler, Gibb & Associates, LLC as the independent registered public accounting firm for the fiscal year ending Dec 31, 2024.
- The Amendment to the Restated Certificate became effective on July 2, 2024.
VolitionRx Limited issued an 8-K to furnish a press release and its 2024 Mid-Year Review pursuant to Regulation FD. The filing does not contain new material financial developments but provides updated operational information via the company's website.
📋 Key Facts
- Filed on June 27, 2024
- Company issued a press release regarding its mid-year review (Exhibit 99.1)
- Included the 2024 Mid-Year Review as an exhibit (Exhibit 99.2)
- Information provided under Item 7.01 is furnished, not filed, meaning it is exempt from certain liabilities under Section 18 of the Exchange Act.
VolitionRx Limited announced its financial results and business updates for the fiscal quarter ended March 31, 2024. The filing serves as a formal notice of the earnings release and an upcoming conference call.
📋 Key Facts
- Financial results for the quarter ended March 31, 2024 were released on May 13, 2024.
- A conference call to discuss results was scheduled for May 14, 2024, at 8:30 a.m. ET.
- The filing includes Exhibit 99.1 containing the full press release.
VolitionRx Limited announced the planned retirement of two long-standing board members, Dr. Martin Faulkes (Executive Chairman) and Dr. Edward Futcher, effective after the 2024 Annual Meeting on July 2, 2024. Additionally, the company amended its bylaws to reduce the quorum requirement from a majority to 33 1/3% of voting power.
🚩 Red Flags
- Significant leadership transition: Departure of the Executive Chairman and long-tenured board members (12 and 7 years respectively).
- Reduction in Board size from eight to six directors.
- Bylaw amendment lowering quorum requirements can be used to facilitate decisions with lower shareholder participation.
📋 Key Facts
- Dr. Martin Faulkes (Executive Chairman) and Dr. Edward Futcher will retire following the July 2, 2024 Annual Meeting.
- Dr. Faulkes served on the Board for over 12 years; Dr. Futcher served for over 7 years.
- The Board size will be reduced from eight to six directors effective after the Annual Meeting.
- Guy Innes appointed as interim Chairman and Chair of Nominations and Governance Committee upon re-election of nominees.
- Bylaws amended to lower quorum requirement from a majority (>50%) to 33 1/3% for stockholder meetings.
VolitionRx Limited announced its financial results and business updates for the fiscal year and quarter ended December 31, 2023. The filing serves as a formal announcement of upcoming earnings communications.
📋 Key Facts
- Financial results for the quarter and fiscal year ended December 31, 2023, were released on March 25, 2024.
- A conference call to discuss these results was scheduled for March 26, 2024, at 8:30 a.m. ET.
- The filing includes Exhibit 99.1 containing the full press release.
VolitionRx Limited announced the appointment of Dr. Andrew Retter as the company's new Chief Medical Officer on March 19, 2024.
📋 Key Facts
- Dr. Andrew Retter appointed as Chief Medical Officer (CMO).
- Announcement date: March 19, 2024.
- The appointment was communicated via a press release filed as Exhibit 99.1.
VolitionRx Limited announced the receipt of $13.0 million in milestone payments from Heska Corporation. The payment was triggered by the successful assay transfer of the Nu.Q® Vet Cancer Test onto Heska’s Element i+ Immunodiagnostic Analyzer.
📋 Key Facts
- Received $13.0 million in milestone payments on December 29, 2023.
- Payer: Heska Corporation.
- Milestone triggered by successful assay transfer of Nu.Q® Vet Cancer Test onto the Element i+ Immunodiagnostic Analyzer.
- Agreement originates from a License and Supply Agreement dated March 28, 2022.